EP1436329A4 - Anticorps anti-pdgf et procedes de production d'anticorps mis au point - Google Patents

Anticorps anti-pdgf et procedes de production d'anticorps mis au point

Info

Publication number
EP1436329A4
EP1436329A4 EP02775937A EP02775937A EP1436329A4 EP 1436329 A4 EP1436329 A4 EP 1436329A4 EP 02775937 A EP02775937 A EP 02775937A EP 02775937 A EP02775937 A EP 02775937A EP 1436329 A4 EP1436329 A4 EP 1436329A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
methods
pdgf
producing engineered
engineered antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02775937A
Other languages
German (de)
English (en)
Other versions
EP1436329A1 (fr
Inventor
Katherine S Bowdish
Shana Frederickson
Anke Kretz-Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of EP1436329A1 publication Critical patent/EP1436329A1/fr
Publication of EP1436329A4 publication Critical patent/EP1436329A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
EP02775937A 2001-09-20 2002-09-20 Anticorps anti-pdgf et procedes de production d'anticorps mis au point Withdrawn EP1436329A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32353701P 2001-09-20 2001-09-20
US32354401P 2001-09-20 2001-09-20
US323537P 2001-09-20
US323544P 2001-09-20
US37999402P 2002-05-13 2002-05-13
US379994P 2002-05-13
PCT/US2002/030086 WO2003025019A1 (fr) 2001-09-20 2002-09-20 Anticorps anti-pdgf et procedes de production d'anticorps mis au point

Publications (2)

Publication Number Publication Date
EP1436329A1 EP1436329A1 (fr) 2004-07-14
EP1436329A4 true EP1436329A4 (fr) 2005-04-27

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02775937A Withdrawn EP1436329A4 (fr) 2001-09-20 2002-09-20 Anticorps anti-pdgf et procedes de production d'anticorps mis au point

Country Status (4)

Country Link
EP (1) EP1436329A4 (fr)
JP (1) JP2005512962A (fr)
CA (1) CA2460587A1 (fr)
WO (1) WO2003025019A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298817A1 (fr) * 2001-12-03 2011-03-23 Alexion Pharmaceuticals, Inc. Anticorps Hybrides
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
JP2006503547A (ja) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 生物兵器防衛のための免疫療法
NZ542988A (en) 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
CA2903196A1 (fr) 2003-08-27 2005-03-10 Ophthotech Corporation Polytherapie pour le traitement de troubles neovasculaires oculaires
CA2561264A1 (fr) * 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2280997A2 (fr) 2008-04-18 2011-02-09 Xencor, Inc. Anticorps monoclonaux d équivalent humain conçus à partir de régions variables non humaines
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
WO2010099364A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
MY175224A (en) 2012-03-15 2020-06-16 Janssen Biotech Inc Human anti-cd27 antibodies, methods, and uses
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
CA2877584A1 (fr) * 2012-06-28 2014-01-03 Molecular Partners Ag Conception de proteines a motifs ankyrine repetes liees au facteur de croissance derive des plaquettes
EP2900250B1 (fr) 2012-09-27 2018-11-07 Allergan, Inc. Systèmes d'administration de médicaments biodégradables permettant une libération prolongée de protéines
CA2902547A1 (fr) 2013-03-14 2014-09-25 Allergan, Inc. Composition d'une administration a liberation soutenue, et procede de stabilisation de proteines durant un processus de fabrication
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024059A1 (fr) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Communication microvasculaire a mediation de pdgf et procedes d'utilisation
WO1999029888A1 (fr) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
US6180370B1 (en) * 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180370B1 (en) * 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
WO1999024059A1 (fr) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Communication microvasculaire a mediation de pdgf et procedes d'utilisation
WO1999029888A1 (fr) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROECKER M ET AL: "Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line.", LIFE SCIENCES. 1998, vol. 63, no. 26, 1998, pages 2373 - 2386, XP002307362, ISSN: 0024-3205 *
CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666 *
See also references of WO03025019A1 *
SHIMIZU S ET AL: "In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, no. 12, December 2000 (2000-12-01), pages 1285 - 951, XP002960893, ISSN: 0910-5050 *
WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP004461859, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2003025019A9 (fr) 2004-05-06
CA2460587A1 (fr) 2003-03-27
EP1436329A1 (fr) 2004-07-14
JP2005512962A (ja) 2005-05-12
WO2003025019A8 (fr) 2004-04-01
WO2003025019A1 (fr) 2003-03-27

Similar Documents

Publication Publication Date Title
EP1436329A4 (fr) Anticorps anti-pdgf et procedes de production d'anticorps mis au point
EP1432444A4 (fr) Anticorps anti-a beta
HK1074206A1 (en) Anti-trail-r antibodies
IL212419A0 (en) Methods of administering anti-tnf antibodies
AU2002346641A8 (en) Apertured non-woven composites and method for making
EP1635872A4 (fr) Anticorps et proteines de fusion comprenant des regions constantes modifiees
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
ZA200305825B (en) Modified antibodies and methods of use
EP1514928A4 (fr) Procede de construction d'anticorps
EP1551447A4 (fr) Anticorps anti-addl et leurs utilisations
AU4002001A (en) High potency recombinant antibodies and method for producing them
HUP0402333A3 (en) Modified anti-tnf alpha antibody
GB0128287D0 (en) Novel method and compounds
TWI346203B (en) Antibody pair screening methods
AU2002365649A8 (en) Anti-dota antibody
AU2002359495A8 (en) Anti-tnf antibodies, compositions, methods and uses
EP1367611A4 (fr) Partie d'inductance et procede de production associe
GB2387599B (en) Methods for producing antibodies
AU2002367943A8 (en) Improved reagents and methods for producing parvoviruses
EP1621616A4 (fr) Anticorps humain d'interleukine-18 antihumaine, fragment de celle-ci et procede d'utilisation correspondant
IL166063A0 (en) Antibodies and uses thereof
EP1380646A4 (fr) Anticorps monoclonal reconnaissant l'acetyllysine et son procede de production
TWI318239B (en) Methods for producing novel medaka and novel medaka
GB0221940D0 (en) Antibody and screening method
EP1336848A4 (fr) Methode hautement efficace de criblage d'anticorps

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050308

17Q First examination report despatched

Effective date: 20050808

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071219